In the lead up to the Australian Federal Budget in May 2023, Australian Health Journal reached out to peak health industry bodies to hear about their priorities, either noted in pre-budget submissions lodged with Federal Government in January 2023 or in recent forums such as the Strengthening Medicare Taskforce.
Others have stated their priorities directly with Federal Government. Through these interviews, AHJ gives a final opportunity to communicate to all health stakeholders, the funding needs for a range of priorities. These range from new models of care to pilots and wholesale, system improvements to building more sustainable workforces to help grow certain sectors of the health system
The CEO of Pathology Technology Australia, Dean Whiting spoke with Australian Health Journal about the following:
- Pathology Technology Australia’s key priorities in the coming years
- Current local capability in pathology technology compared to other countries
- How the health system supports change and adoption of pathology technology
- How pathology is perceived by the public and in government as well as how developments in pathology technology are followed and understood
- Observations in the Strengthening Medicare Taskforce Report
And lastly Dean looks towards the Federal Budget this year and in 2024 for the adoption of currently unfunded pathology tests, that could alter pathology as a cost centre to one that saves the health system considerable money.
You Might also like
-
Medicinal cannabis in Australia Update
According to the Australian Journal of General Practice, published by the Royal Australian College of General Practitioners, more than 130,000 medicinal cannabis approvals have been issued in Australia to date, mostly by general practitioners, with approximately 65% of these to treat chronic non-cancer pain. Despite robust supportive data from animal models, current clinical trial evidence for THC and CBD efficacy in chronic pain is incomplete. In their prescribing decisions, doctors must balance patient demand and curiosity with caution regarding potential risks and limited efficacy (Source: https://www1.racgp.org.au/ajgp/2021/october/medicinal-cannabis)
Australian Health Journal met with 3 speakers at the recent @arcsaustralia ARCS22 Conference providing an update on medicinal cannabis. The discussion with the speakers now centres on affordability and access.
-
Gavin Fox-Smith talks Medical Technology
Former Johnson & Johnson ANZ Managing Director, Gavin Fox-Smith on working in large & small MedTech companies
-
ACN National Nursing Forum 2019
The Australian College of Nursing National Nursing Forum was held in Hobart Tasmania in August 2019.